Pluri Inc. (PLUR) Stock Ticker

About Pluri Inc.

Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.

PLUR stock facts

What you can see for PLUR on Tickr

Live PLUR price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the PLUR report.

Rankings